CHU de Bordeaux
Bordeaux, 33000, France
NCT Number: NCT02821234
One-tenth of the population suffers from insomnia, increasing their risk on other health problems such as depression. Self-reported sleep quality only was historically leading for insomnia diagnosis, but more recently a state of 24-hour hyperarousal has been associated with insomnia, either physiological (increased heart rate, higher frequency EEG) or predominant cognitive-emotional hyperarousal (worry, rumination, repetitive thoughts). Strong evidence shows that those suffering from insomnia with physiological hyperarousal are at higher risk of short and long term severe health problems such as inflammation and hypertension than the group without physiological hyperarousal. The neurophysiological basis of these insomnia phenotypes has however barely been investigated, although its results can have major consequences for how this limiting condition will be treated.
To support the development of a differential diagnosis of insomnia, structural and functional brain connectivity in insomnia patients with different levels of hyperarousal will be investigated and related to sleep variables. Investigators will compare the insomnia group to a normal sleeping control group. Investigators expect that the emotion processing circuit (amygdala-ventromedial prefrontal cortex) is a) more affected in insomniacs compared to normal sleeping controls and b) the directionality of this effect to depend on the level and type of hyperarousal in insomniacs. Further, investigators expect c) amygdala activity to be positive correlated with physiological hyperarousal level and d) prefrontal activity to be positively correlated with cognitive-emotional hyperarousal level. Investigators expect a higher physiological hyperarousal level to be reflected in affected afferent pathways of the amygdala towards the ventromedial prefrontal cortex and investigators expect higher cognitive-emotional hyperarousal to be related to affected efferent pathways from the ventromedial prefrontal cortex to the amygdala. Investigators expect sleep quality to play a mediating role in both types of hyperarousal and their brain activation patterns in insomnia patients and normal sleeping controls.
These data can lead to the definition of new insomnia phenotypes and to new customized and effective insomnia treatment, focused not only on improving sleep but also on changing dysfunctional hyperarousal levels that currently put insomniacs at risk of numerous severe health problems.
Looking for future studies?
Notify Me20 year–50 year
All sexes
Interventional
Not applicable
Bordeaux, 33000, France
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: During Visit V2 (study termination), up to 3 month after consent signature
Time frame: During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Time frame: During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Time frame: During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Time frame: During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Time frame: During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Time frame: During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Time frame: During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Time frame: During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Time frame: During Pre-inclusion Visit, at consent signature
Time frame: During Pre-inclusion Visit, at consent signature
Time frame: During Pre-inclusion Visit, at consent signature
Time frame: During Pre-inclusion Visit, at consent signature
Time frame: During Inclusion Visit, up to 1 month after consent signature
Time frame: During Inclusion Visit, up to 1 month after consent signature
Time frame: During Visit V2 (study termination), up to 3 month after consent signature
Time frame: During Visit V2 (study termination), up to 3 month after consent signature
University Hospital, Bordeaux
Other
Acronym: SOMNET
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05956886
Dyssomnias, Glucose Metabolism Disorders
Newark, Delaware, United States
View Trial DetailsNCT03665337
Delayed Sleep Phase, Dyssomnias
San Francisco, California, United States
View Trial DetailsNCT07417163
Cirrhosis, Dyssomnias
Boston, Massachusetts, United States
View Trial DetailsNCT04936321
Brain Diseases, Central Nervous System Diseases
Seattle, Washington, United States
View Trial Details